These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38858597)

  • 1. ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response.
    Lim LQJ; Adler L; Hajaj E; Soria LR; Perry RB; Darzi N; Brody R; Furth N; Lichtenstein M; Bab-Dinitz E; Porat Z; Melman T; Brandis A; Malitsky S; Itkin M; Aylon Y; Ben-Dor S; Orr I; Pri-Or A; Seger R; Shaul Y; Ruppin E; Oren M; Perez M; Meier J; Brunetti-Pierri N; Shema E; Ulitsky I; Erez A
    Nat Metab; 2024 Jul; 6(7):1294-1309. PubMed ID: 38858597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.
    Rabinovich S; Adler L; Yizhak K; Sarver A; Silberman A; Agron S; Stettner N; Sun Q; Brandis A; Helbling D; Korman S; Itzkovitz S; Dimmock D; Ulitsky I; Nagamani SC; Ruppin E; Erez A
    Nature; 2015 Nov; 527(7578):379-383. PubMed ID: 26560030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53.
    Miyamoto T; Lo PHY; Saichi N; Ueda K; Hirata M; Tanikawa C; Matsuda K
    Sci Adv; 2017 May; 3(5):e1603204. PubMed ID: 28560349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism.
    Khare S; Kim LC; Lobel G; Doulias PT; Ischiropoulos H; Nissim I; Keith B; Simon MC
    Cancer Metab; 2021 Dec; 9(1):40. PubMed ID: 34861885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer.
    Silberman A; Goldman O; Boukobza Assayag O; Jacob A; Rabinovich S; Adler L; Lee JS; Keshet R; Sarver A; Frug J; Stettner N; Galai S; Persi E; Halpern KB; Zaltsman-Amir Y; Pode-Shakked B; Eilam R; Anikster Y; Nagamani SCS; Ulitsky I; Ruppin E; Erez A
    Cancer Res; 2019 Feb; 79(3):518-533. PubMed ID: 30573518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor.
    Zou Z; Hu X; Luo T; Ming Z; Chen X; Xia L; Luo W; Li J; Xu N; Chen L; Cao D; Wen M; Kong F; Peng K; Xie Y; Li X; Ma D; Yang C; Chen C; Yi W; Liu O; Liu S; Luo J; Luo Z
    Nat Commun; 2021 Apr; 12(1):2263. PubMed ID: 33859183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
    Verma M; Charles RCM; Chakrapani B; Coumar MS; Govindaraju G; Rajavelu A; Chavali S; Dhayalan A
    J Mol Biol; 2017 Jul; 429(15):2278-2289. PubMed ID: 28587924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Kaposi's Sarcoma-Associated Herpesvirus Upregulates Argininosuccinate Synthase 1, a Rate-Limiting Enzyme of the Citrulline-Nitric Oxide Cycle, To Activate the STAT3 Pathway and Promote Growth Transformation.
    Li T; Zhu Y; Cheng F; Lu C; Jung JU; Gao SJ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30463977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular vesicles from human liver stem cells restore argininosuccinate synthase deficiency.
    Herrera Sanchez MB; Previdi S; Bruno S; Fonsato V; Deregibus MC; Kholia S; Petrillo S; Tolosano E; Critelli R; Spada M; Romagnoli R; Salizzoni M; Tetta C; Camussi G
    Stem Cell Res Ther; 2017 Jul; 8(1):176. PubMed ID: 28750687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXO3a-regulated arginine metabolic plasticity adaptively promotes esophageal cancer proliferation and metastasis.
    Sun W; Kou H; Fang Y; Xu F; Xu Z; Wang X; Yin R; Zhang Q; Jiang Q; Xu Y
    Oncogene; 2024 Jan; 43(3):216-223. PubMed ID: 38049565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASS1 deficiency is associated with impaired neuronal differentiation in zebrafish larvae.
    Seidl MJ; Scharre S; Posset R; Druck AC; Epp F; Okun JG; Dimitrov B; Hoffmann GF; Kölker S; Zielonka M
    Mol Genet Metab; 2024 Jan; 141(1):108097. PubMed ID: 38113552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
    Barnett SE; Kenyani J; Tripari M; Butt Z; Grosman R; Querques F; Shaw L; Silva LC; Goate Z; Marciniak SJ; Rassl DM; Jackson R; Lian LY; Szlosarek PW; Sacco JJ; Coulson JM
    Mol Cancer Res; 2023 May; 21(5):411-427. PubMed ID: 36669126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic adenosine monophosphate-induced argininosuccinate synthase 1 expression is essential during mouse decidualization.
    Huang Z; Wang TS; Zhao YC; Zuo RJ; Deng WB; Chi YJ; Yang ZM
    Mol Cell Endocrinol; 2014 May; 388(1-2):20-31. PubMed ID: 24556046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.
    Miao YQ; Chen W; Zhou J; Shen Q; Sun Y; Li T; Wang SC
    Bioengineered; 2022 Jan; 13(1):1858-1871. PubMed ID: 35012429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis.
    Luo W; Zou Z; Nie Y; Luo J; Ming Z; Hu X; Luo T; Ouyang M; Liu M; Tang H; Xie Y; Peng K; Chen L; Zhou J; Luo Z
    Cell Death Dis; 2024 May; 15(5):319. PubMed ID: 38710705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
    Kim Y; Kobayashi E; Kubota D; Suehara Y; Mukaihara K; Akaike K; Ito A; Kaneko K; Chuman H; Kawai A; Kitano S
    Oncotarget; 2016 Oct; 7(43):70832-70844. PubMed ID: 27683125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.
    Li JM; Yang DC; Oldham J; Linderholm A; Zhang J; Liu J; Kenyon NJ; Chen CH
    Mol Ther; 2021 Apr; 29(4):1487-1500. PubMed ID: 33508432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.